Frontlight ResearchEarly access
WithdrawnPhase 2
Improving Beta-2 Adrenergic Signaling in Alzheimer's Disease
Key facts
- Who runs it
- Palo Alto Veterans Institute for Research
- Where
- Palo Alto, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Phase
- Phase 2
- Started
- Jan 2023
- Ended
- Jul 2025
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Formoterol A
- Formoterol B (placebo)
- Record updated
- 16 September 2020
- Why it stopped
- Funding ran out before study started, prior PI left institution.
Who can take part
- Age
- 50 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- Males and females between the ages of 50-85,
- Mild-to-moderate AD (NINCDS/ADRDA criteria for probable AD will be used to establish AD diagnosis)
- MMSE 16-26
Who cannot take part
- Use of another beta2 adrenergic drug within the last 2 months
- Known hypersensitivity or prior exposure to formoterol
- Non-AD dementia or significant neurological disease such as Parkinson's disease, stroke, brain tumor,multiple sclerosis, seizure disorder, focal brain lesion, or head injury with loss of consciousness
- Active asthma or family history of asthma
- Hypothyroidism, congestive heart failure (New York Heart Association Class III or IV), significant extrapyramidal symptoms on neurological examination, serum creatinine>1.3 mg/dl, significant arrhythmias or conduction defect abnormalities on ECG,
- Evidence of any significant clinical disorder or laboratory finding that renders the person unsuitable for receiving an investigational new drug
- Residence in a long-term care facility
Where in United States
- VA Palo Alto Health Care SystemPalo Alto, United States
About the trial
What the trial wants to find out
The purpose of this study is to test the effects of long-term therapeutic doses of formoterol, on a) cerebrospinal fluid (CSF) tau levels, and Amyloid Beta protein 40/42 levels in the CSF, and b) cognitive function in people with mild to moderate Alzheimer' Disease (AD).
The 2 groups in the trial
- Formoterol AExisting treatment, for comparison
12 months, formoterol, 20microgram/2ml, inhaler, BID
- Formoterol BPlacebo, for comparison
12 months, normal saline, 2ml, inhaler, BID
Treatment: Formoterol B (placebo)
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 16 September 2020